Effectiveness of interventions for middle-aged and ageing population with neck pain: a systematic review and network meta-analysis protocol

Uchukarn Boonyapo,1,2 Alison B Rushton,3 Nicola R Heneghan,4 Piyameth Dilokthornsakul,5 Nattawan Phungwattanakul,1 Taweewat Wiangkham

ABSTRACT

Introduction Neck pain (NP) is a common musculoskeletal complaint and is increasing in prevalence. Current clinical practice guidelines and systematic reviews recommended conservative, pharmacological and invasive interventions for individuals with NP. However, optimal management specifically for those who are middle-aged or older adults (≥45 years) is not available; and important considering our ageing population.

Methods and analysis A systematic review with network meta-analysis (NMA) will be conducted following the Cochrane guidelines. Eligibility criteria include randomised controlled/trials evaluating any of acute (<3 months) or chronic (≥3 months) non-specific NP, whiplash associated disorders, cervical radiculopathy and cervicogenic headache. Any interventions and outcome measures detailed within The International Classification of Functioning, Disability and Health domains will be included. Two independent reviewers will search key databases (AMED, CENTRAL, CINAHL, Embase, MEDLINE, PEDro and PsycINFO), grey literature, key journals and reference lists in May 2022. Two reviewers will decide eligibility and assess risk of bias (ROB) of included studies. The kappa statistic will be used to evaluate agreement between the reviewers at each stage. Data will be extracted by one reviewer and checked for accuracy by a second reviewer. Descriptive data and ROB will be summarised and tabulated. Traditional pairwise meta-analysis using random-effect model will be performed for all direct comparisons, and NMA using a frequentist random-effect model then performed based on NP classification where possible. A network of traditional pairwise meta-analysis allows comparisons of multiple interventions from both direct and indirect evidence to provide a hierarchical establishment for enhancing decision making of clinical practitioners.

Ethics and dissemination Ethic approval is not required as the study is a literature review. The findings will be shared with the national and international researchers, healthcare professionals and the general public through publishing in a peer-reviewed journal and presentations at conferences.

PROSPERO registration number CRD42021284618.
years.2 Also, among age 50–75 years, NP was ranked in the top 25 leading causes of DALYS in 2019, rising from the 32 in 1990.10 Approximately 20% of older adults 70 years and above experience NP once a month,11 contributing to poorer self-rated health and comorbidities.12 To promote health and well-being in older age in accordance with World Population Ageing report 2015 by United Nations,13 addressing management of NP in those aged 45 and older is important.

NP is a complex biopsychosocial disorder and management is challenging.14 Recent clinical practice guidelines and systemic reviews broadly recommend conservative treatments, medication and invasive treatment for individuals with NP.14–26 Different classifications (eg, mobility deficits, movement coordination impairment, cervicogenic, radiculopathy) and duration (eg, acute, subacute and chronic) of NP require different treatment approaches.14 For example, manual therapy is highly recommended for NP with mobility deficits,14 while NP with neuropathic pain is associated with increased need for medication.27 However, considering older adults, interventions must be selected cautiously because of possible risks such as drug interactions and comorbidities.28 Moreover, factors associated with NP in older adults are not only limited to pain, disability, depression,29 pain catastrophising30 and QoL but also include impaired balance31 and memory decline32 which could be important and frequently overlooked clinical outcomes. As a result, management in this specific population remains unclear. In the absence of population specific guidance, a review focused to individuals with NP age 45 years and above is now needed.

Objective
This review aims to systematically evaluate and synthesise the effectiveness of interventions for middle aged and ageing population aged 45 and older with NP.

METHODS
Design
A systematic review and NMA will be conducted in accordance with guidelines in the Cochrane Handbook.33 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Protocols was used to report the protocol.34 and the review will be reported in adherence with the PRISMA extension statement for incorporating network meta-analysis (NMA).35

Eligibility criteria
The Population Intervention Comparison Outcome Study Design (PICOS) framework was used to develop eligibility criteria.36 Selected included studies should meet the following criteria:

Population
Participants aged 45 years and older with NP with or without pain referred into the upper limb(s) that lasts for at least 1 day37 will be included. Also, individuals with any of the four common classifications of NP14 will be included, defined as (1) non-specific (or idiopathic or mechanical) NP; (2) traumatic NP or whiplash associated disorder (WAD); (3) NP with radicular pain or cervical radiculopathy and (4) NP with headache or cervicogenic headache (CGH). For each category, duration of NP less than 3 months will be defined as acute,38–40 while pain equal or more than 3 months will be defined as chronic.41 42

Interventions
Interventions may comprise:
► Conservative interventions, for example: cognitive—behavioural therapy24 exercise,13 manual therapy,21 massage,25 patient education39 and multidisciplinary approaches.22
► Pharmacological Interventions, for example: antidepressant, non-steroidal anti-inflammatory drugs, opioids, muscle relaxants, paracetamol and topical agents (non-opioids).28
► Invasive interventions, for example: anterior or posterior surgical approaches for cervical spine15 and cervicothoracic sympatheticctomy.14

Comparator
Comparators can include alternative treatment options or a control condition such as placebo/sham, usual care, standard intervention or no-intervention.

Outcome measures
Both patient-reported and performance-based clinical outcomes using a reliable and valid instrument measure for this specific population will be included. Outcome measures detailed within physical, psychological, social and cultural contexts based on a framework from The International Classification of Functioning, Disability and Health will be included.36

Study design
Only randomised controlled trials or randomised clinical trials or randomised controlled clinical trials (RCTs) will be included.

Studies will be excluded if:
1. It did not focus on the effectiveness of interventions as key outcomes.
2. It has not evaluated NP separately from other musculoskeletal disorders, resulting in differential effectiveness of the interventions strategies of interest.
3. It considered a participant with specific underlying pathologies that requires specific approaches such as tumours, infection, inflammatory disorders, fibromyalgia or widespread pain disorder, neck injury that resulted in a spinal dislocation and fracture, osteoporosis, rheumatological condition or ankylosing spondylitis.
4. It was not published in English.
(AMED), Cochrane Central Register of Controlled Trial (CENTRAL), Cumulative Index to Nursing and Allied Health (CINAHL), Excerpta Medica Database from Elsevier (Embase), Medical Literature Analysis and Retrieval System Online (MEDLINE), Physiotherapy Evidence Database (PEDro) and Psychological Information Database (PsycINFO).

Additional searches in key journals will be performed manually including, for example, Geriatric Rehabilitation, Journal of Aging and Health, Advances in Aging Research, European Spine Journal, Journal of Orthopaedic and Sports Physical Therapy, Physiotherapy, BMC Musculoskeletal Disorders, Musculoskeletal Science and Practice and Neurosurgery. To avoid publication bias and overestimation of treatment effects, grey literature (eg, Practice and Neurosurgery. To avoid publication bias and overestimation of treatment effects, grey literature (eg, Zetoc, OpenGrey and Google Scholar) and unpublished literature (WHO International Clinical Trials Registry Platform (ICTRP)) will be explored. Potentially eligible studies will be considered from relevant systematic review and the reference lists of the included studies.

Search strategy
The strategy is informed by the PICOS criteria based on groups of search terms including: (1) NP (one of four common classifications); (2) middle-aged and ageing population and (3) RCTs. Different interventions, comparators and outcome measures are included in this review, no search terms will be used for those to avoid exclusion of potentially relevant studies. The examples of search terms and search strategies used are provided in the example below.

Search string for Ovid MEDLINE(R) 1946 to August week 4 2021.
1. exp neck pain/
2. (ache, neck or aches, neck or cervical pain or cervical pain, posterior or neckache or neckaches or posterior or cervical pain or posterior neck pain or idiopathic neck pain or neck pain with mobility deficits).mp.
3. (pain neck shoulder or myofascial neck pain or non-specific neck pain or NSNP or acute non-specific neck pain or acute neck pain or chronic neck pain or chronic non-specific neck pain or CNSNP or neck pain with mobility deficits or cervical spondylosis).mp.
4. 1 or 2 or 3
5. exp Radiculopathy/
6. (cervical radiculopathy or neck pain with radicular pain or nerve root avulsion or nerve root compression or nerve root disorder or nerve root inflammation or cervical disc herniation or herniated disc or cervical stenosis or cervical spondylolysis or cervical spondylolisthesis).mp.
7. Neck pain with radiation.mp.
8. referred pain.mp.
9. 5 or 6 or 7 or 8
10. exp neck injuries/
11. exp Whiplash Injuries/
12. (acute whiplash or acute whiplash injury or acute whiplash associated disorder or acute WAD or chronic whiplash or chronic whiplash injury or chronic whiplash associated disorder or chronic WAD or WAD or traumatic neck disorder).mp.
13. 10 or 11 or 12
14. exp Post-Traumatic Headache/
15. Cervicogenic Headache.mp.
16. (Neck pain with headache or secondary headache or secondary headache disorder).mp.
17. 14 or 15 or 16
18. 4 or 9 or 13 or 17
19. exp Aged/
20. (aged or elderly or aging or elder or senior or old or older or pre-aging or pre-elderly).mp.
21. exp Middle Aged/
22. 19 or 20 or 21
23. exp “Randomized Controlled Trials as Topic”/
24. (clinical trials, randomized or controlled clinical trials, randomized or “randomized controlled trials as topic” or trials, randomized clinical).mp.
25. randomi?ed.ab.
26. 23 or 24 or 25
27. 18 and 22 and 26

Study records
Data management
Microsoft Endnote will be used to store the imported search results, remove duplicates and manage bibliographies.

Selection process
Two reviewers (UB and NP) will independently search and screen titles and abstracts full texts and exclude studies not meeting the criteria; reporting all reasons for exclusion. The potentially eligible papers will be classified as eligible/not eligible/unclear and then compared between the two reviewers after the searching process. The two reviewers will meet and discuss if there are possible differences. A third reviewer (TW) will resolve disagreements at any stage through discussion. The process of study selection will be reported using a PRISMA flow diagram.

Data collection process
The data for each paper will be extracted by the first reviewer (UB) and checked for accuracy by the second reviewer (NP) using the Cochrane ‘Data collection forms for intervention reviews: RCTs only’.46 The form will be piloted by the first reviewer and checked by the second reviewer on five random eligible studies. A third reviewer (TW) will mediate any disagreements.

Both dichotomous and continuous outcomes data will be extracted. The outcome data (eg, means and SD) will be extracted to investigate time points of follow-up that could be divided into short-term (<3 months), medium-term (3–12 months) and long-term effects (≥12 months).26 In a case of available data of participants with...
a variety of age ranges or unavailable data, data will be recoded from only participants age over 45 if possible, or trial authors will be contracted once for further information via email. A reminder email will be sent 2 weeks after. If there are no responses within 3 weeks, we will assume that the data is not available or we will estimate the mean and SD following Cochrane recommendations.

Data items
The extracted information will be recorded in a ‘characteristics of included studies’ table to further investigate statistical analysis.45 This includes:
1. Study identifiers (eg, trial authors, publication date).
2. Study characteristics (eg, study setting, location, source of financial support).
3. Participant information (eg, age, gender ratio, sample size, clinical conditions, duration and severity of NP).
4. Intervention data (eg, type of intervention used, duration of treatment, dosage).
5. Clinical outcomes (eg, measurements used, follow-up period, main results).

Risk of bias assessment of individual studies
The risk of bias assessment tool used in this review is the revised Cochrane risk of bias tool for randomised trials (ROB 2.0) which is suitable for assessing biases of relative effects of two interventions (experimental and comparator interventions) on a particular outcome in RCTs.46 Studies will be evaluated according to the following response options for the signalling questions: ‘no’ or ‘probably no’ (considered as high risk of bias), ‘yes’ or ‘probably yes’ (considered as low risk of bias) and no information (indicated some concerns). The overall risk of bias will be assessed based on five domains at each stage including the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result.46

The risk of bias of all included studies will be independently evaluated by two reviewers (UB and NP). The kappa statistic will be used to evaluate agreement between the two reviewers, where>0.75 is excellent agreement, 0.60–0.74 is good agreement and 0.40–0.59 is fair agreement.48 50 Calibration exercise for the risk of bias assessment and kappa analysis will be piloted on five excluded studies to assess inter-rater reliability.51 The third reviewer will resolve any conflicts through discussion as needed.

Data synthesis
Our approaches to data synthesis utilises multiple stages of a general framework from Cochrane Recommendation.52 To determine which studies are similar enough to be grouped and what data are available for synthesis, descriptive data will be presented in a table of key characteristics of included eligible studies illustrating summaries of key study and participants’ characteristics, interventions, patient-reported and performance-based outcomes and risk of bias assessment. The numbers and process of including/excluding papers will be reported on a PRISMA flow chart.

Assessment of heterogeneity
This review will include both pairwise and network comparisons. For the traditional pairwise meta-analysis, the heterogeneity within the studies will be examined by visually screening the forest plots.52 As there are various types of intervention included, heterogeneity between studies will be assessed with respect to the classification and duration of NP. I² statistic will be used to evaluate statistical heterogeneity and interpreted based on Cochrane Handbook for systematic review of Interventions (0%–40%=might not be important, 30%–60%=may represent moderate, 50%–90%=substantial and 75%–100%=considerable heterogeneity).53 In the event of significant statistical heterogeneity where meta-analysis is not possible, all data will be redetermined for possible sources of heterogeneity and other statistical analysis methods such as combining p value or summary of effect estimates will be considered as appropriate.52 In contrast, if there is low heterogeneity (I² <50%), a quantitative synthesis will be performed as described below.

Methods for pairwise meta-analysis
Meta-analyses using a random-effect model for each specific intervention comparisons will be completed for all available interventions. This will be undertaken for all direct comparisons following Cochrane Handbook guidelines.55 Dichotomous outcomes will be determined using risk ratio with 95% CI. Continuous outcomes will be analysed by mean difference or standardised mean difference (with 95% CI) in cases of different measurement scales used. The intervention effect estimates will be pooled using weighted mean differences with 95% CI. Tables and a forest plot will be used to report the quantitative data.

Methods for NMA
To investigate the comparative effectiveness of different interventions regarding each NP category, NMA will allow some interventions that were not directly compared with others to be interpreted along with the entire body of the evidence.54 The effectiveness of interventions can be estimated by using multiple direct and indirect evidence from a generalisation of traditional pairwise meta-analysis.48 55 In this review, NMA will be performed using a frequentist random-effect model with the methodology of multivariable meta-analysis to assess consistency of the comparative effectiveness of eligible interventions56 57 using STATA (V.14).

Although there is similarity between network and conventional meta-analysis, key different assumptions are transitivity (influences from effect modifiers on indirect comparisons) and coherence (similarity between direct and indirect effect estimates).48 Coherence will be explored by comparing direct and indirect evidence using a design by treatment interaction model (Global approach).58 Global inconsistency will be indicated significant if the
two-sided of the test equal 0.05. Moreover, we will use a network diagram and league table to present mixed treatment effect sizes from combining direct and indirect evidence of interventions.

Subgroup analysis and investigation of heterogeneity
Because intervention responses can be affected by participants’ characteristics, it is important to identify the possible sources (effect modifiers) in the NMA review. We hypothesise the potential effect modifiers as:
- Clinical conditions: (1) non-specific (or idiopathic or mechanical) NP; (2) traumatic NP or WAD; (3) NP with radicular pain or cervical radiculopathy and (4) NP with headache or CGH.
- Severity of NP: measured by valid and reliable instruments, for example, 11-point Numeric Pain Rating Scale.
- Duration of NP: acute (<3 months) or chronic (≥3 months).
- Duration of follow-up: short-term (<3 months), medium-term (3–12 months) and long-term effects (≥12 months).
- Dosage of treatment: for example, how many sessions per week and the number of treatment sessions.

Confidence in cumulative evidence
Grading of Recommendations, Assessment, Development and Evaluation will be used to report the overall quality of the evidence in NMA. The certainty of evidence will be evaluated for each important outcome based on five domains which are risk of bias, consistency of effect, imprecision, indirectness and publication bias. The quality of evidence can be downgraded up to two levels across the five domains and will be rated as ‘very low’, ‘low’, ‘moderate’, or ‘high’ quality. This will be assessed by the two independent reviewers (UB and NP) for each treatment effect, and a third reviewer (TW) will mediate any disagreement until consensus is reached. The detailed information and certainty of the evidence will be reported in the ‘Summary of findings’ tables.

Implications
This systematic review will provide evidence for the effectiveness of interventions for middle-aged and ageing population with NP and NMA can rank the most effective interventions statistically. NMA evaluates both direct and indirect evidence so the effect estimates would be more precise than evaluating direct studies alone. The results of this review will evaluate and summarise a quality of the evidence that will be beneficial for researchers to conduct a better study methodology and high quality in reporting results in the future. Furthermore, in clinical practice, practitioners can be supported by the establishment of a hierarchy of interventions evidence for better decision making.

Ethics and dissemination
Ethic approval is not required for this review as the study is literature review, and direct contact with patients or concerns related to patient privacy are not involved. The results of this review will be disseminated through publication in a peer-reviewed scientific journal and presented at conferences for sharing with the national and international scientific community, healthcare professionals and the general population.

Author affiliations
1Department of Physical Therapy, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand
2Exercise and Rehabilitation Sciences Research Unit, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand
3School of Physical Therapy, Faculty of Health Sciences, Western University, London, Ontario, Canada
4School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK
5Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

Twitter Alison B Rushton @abrushton and Nicola R Heneghan @HeneghanNicola

Contributors UB, TW, AB, NRH and PD contributed concept, design and methodological decisions. UB and TW drafted the initial manuscript and manuscript development. UB, TW and NP will perform the systematic review and meta-analysis. UB, TW, AB, NRH, PD and NP will contribute data interpretation, conclusions and dissemination. All authors read and agreed the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Uchukam Boonyapo http://orcid.org/0000-0001-8453-6264
Alison B Rushton http://orcid.org/0000-0001-8114-7669
Nicola R Heneghan http://orcid.org/0000-0001-7599-3674
Pyameth Dilokthornsakul http://orcid.org/0000-0002-6881-1771
Taweewat Wiangkham http://orcid.org/0000-0003-4115-704X

REFERENCES
1 Hurwitz EL, Randhawa K, Yu H, et al. The global spine care initiative: a summary of the global burden of low back and neck pain studies. European Spine Journal 2018;27:796–801.
2 Safiri S, Kolahi A-A, Hoy D, et al. Global, regional, and national burden of neck pain in the general population, 1990-2017: systematic analysis of the global burden of disease study 2017. BMJ 2020;368:m791.
3 Dielemans JL, Baral R, Binger M, et al. Us spending on personal health care and public health, 1996-2013. JAMA 2016;316:2627–26.
4 Hurwitz EL, Randhawa K, Yu H, et al. The global spine care initiative: a summary of the global burden of low back and neck pain studies. Eur Spine J 2018;27:796–801.
5 Haldeman S, Carroll L, Cassidy JD. Findings from the bone and joint decade 2000 to 2010 Task Force on Neck pain and its associated disorders. J Occup Environ Med 2010;52:424–7.
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777–84.

37 Caldwell DM. Systematic reviews: CRD’s guidance for undertaking reviews in health care. University of York, York Centre for reviews and dissemination; 2009.

38 Guzman J, Hurwitz EL, Carroll LJ, et al. A new conceptual model of neck pain: linking onset, course, and care: the bone and joint decade 2000-2010 Task force on neck pain and its associated disorders. *J Manipulative Physiol Ther* 2009;32:517–28.

39 Wiangkham T, Duda J, Haque MS, et al. A cluster randomised, double-blind pilot and feasibility trial of an active behavioural physiotherapy intervention for acute whiplash-associated disorder (WADII). *PLoS One* 2019;14:e0215803.

40 Wiangkham T, Duda J, Haque MS, et al. Development of an active behavioural physiotherapy intervention (ABPI) for acute whiplash-associated disorder (WAD) II management: a modified Delphi study. *BMJ Open* 2016;6:e011764.

41 Wiangkham T, Uthakhup S, Rushton AB. Pragmatic cluster randomised double-blind pilot and feasibility trial of an active behavioural physiotherapy intervention for acute non-specific neck pain: a mixed-methods protocol. *BMJ Open* 2019;9:e029795.

42 World Health Organization. International statistical classification of diseases and related health problems; 11th ed.; ICD-11; 2020.

43 Gross A, Kay TM, Paquin J-F, et al. Exercises for mechanical neck disorders. *Cochrane Database Syst Rev* 2020;2020:CD004250.

44 Straube S, Derry S, Moore RA, et al. Cervico-Thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. *Cochrane Database Syst Rev* 2013;2020.

45 Dwan K, Gamble C, Williamson PR, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. *PLoS One* 2013;8:e68684.

46 Cochrane Training. Data collection form for intervention reviews: RCTs and non-RCTs, 2014. Available: http://training.cochrane.org/resource/data-collection-forms-intervention-reviews [Accessed 31 May 2021].

47 Li T, Higgins JPT, Deeks JJ. Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, et al, eds. *Welch VaCochrane Handbook for systematic reviews of interventions version 6.2* (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current

48 Higgins JPT, Savović J, Page MJ, Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al, eds. *Welch VaCochrane Handbook for systematic reviews of interventions version 6.2* (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current

49 Sterne JAC, Savović J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.

50 Orwin R. Evaluating coding decisions. In: Cooper H, Hedges L, eds. The *Handbook of research synthesis*. New York: Russell Sage Foundation, 1994.

51 Minozzi S, Cinquinii M, Gianola S, et al. The revised Cochrane risk of bias tool for randomized trials (rob 2) showed low interrater reliability and challenges in its application. *J Clin Epidemiol* 2020;126:37–44.

52 McKenzie JE, Brennan SE, Ryan RE. Chapter 9: Summarising study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, et al, eds. *Welch VaCochrane Handbook for systematic reviews of interventions version 6.2* (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current

53 Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al, eds. *Cochrane Handbook for systematic reviews of interventions version 6.2* (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current

54 Mavridis D, Giannatsi M, Cipriani A, et al. A primer on network meta-analysis: with emphasis on mental health. *Evid Based Ment Health* 2021;24:40–6.

55 Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;331:897–900.

56 White IR. *Network meta-analysis*. *Stat J* 2015;15:951–85.

57 White IR, Barrett JM, Snowden D. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012;3:111–25.
58 Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98–110.
59 Cipriani A, Higgins JPT, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130–7.
60 Donegan S, Williamson P, D’Alessandro U, et al. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods 2013;4:291–323.
61 Pankh P, Santaguida P, Macdermid J, et al. Comparison of CPG’s for the diagnosis, prognosis and management of non-specific neck pain: a systematic review. BMC Musculoskelet Disord 2019;20:81.
62 Sarrami P, Armstrong E, Naylor JM, et al. Factors predicting outcome in whiplash injury: a systematic meta-review of prognostic factors. Journal of Orthopaedics and Traumatology 2017;18:9–16.
63 Lam KN, Rushton A, Thoomes E, et al. Neck pain with radiculopathy: a systematic review of classification systems. Musculoskelet Sci Pract 2021;54:102389.
64 Headache Classification Committee of the International Headache Society (IHS). The International classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.
65 Fejer R, Jordan A, Hartvigsen J. Categorising the severity of neck pain: establishment of cut-points for use in clinical and epidemiological research. Pain 2005;119:176–82.
66 Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9:e99682.
67 Schünemann HJ, Higgins JPT, Vist GE. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, eds. Cochrane Handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current
68 Chaimani A, Caldwell DM, Li T. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, eds. Cochrane Handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current
69 Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61:455–63.
70 Bagg MK, Salanti G, McAuley JH. Comparing interventions with network meta-analysis. J Physiother 2018;64:128–32.
71 Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80–97.